Acupuncture for Diabetic Gastroparesis
NCT00470795 · Status: SUSPENDED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 40
Last updated 2008-12-16
Summary
Gastroparesis is a common complication of prolonged diabetes mellitus, both with Type 1 and Type 2 forms. Treatment of diabetic gastroparesis ranges from changing dietary habits to medications and invasive procedures, all of which offer only partial and transient relief, with some options having potentially harmful effects. Acupuncture is an ancient treatment which has been found to be beneficial for many ailments, including those involving the gastrointestinal tract. We propose to evaluate whether acupuncture is an effective and safe treatment for diabetic gastroparesis using a randomized, double-blind, placebo/sham-controlled crossover trial. Because symptoms of gastroparesis do not correlate well with objective tests of gastric emptying (i.e., scintigraphy or 13C breath tests), our primary outcome value will be the Gastroparesis Cardinal Symptom Index (GCSI), a reliable and validated instrument for quantifying symptoms in these patients. As a secondary outcome we will measure gastric emptying using a C13-acetate breath test, as well as the SF-12 Short Form Health Survey. Blinding of the participants will be evaluated using a Validation of Blinding Questionnaire at the end of the treatment period.
Diabetic patients suffering from moderate gastroparesis (total GCSI score \> 2.50) who fulfill the inclusion criteria (and none of the exclusion criteria) will be eligible to participate in the study. On induction, participants will fill out the GCSI questionnaire and SF-36 survey, and will undergo a C13-acetate breath test. They will then be randomly assigned to either true acupuncture treatment or placebo/sham acupuncture treatment. Each participant will undergo 8 treatments twice-weekly, for a period of 4 weeks. At the end of the eighth treatment session, each participant will again fill out a GCSI questionnaire and SF-12 form, as well as repeating the C13-acetate breath. Following a 4-week washout period, patients will be crossed over to either placebo/sham or true acupuncture treatment, again 8 twice-weekly treatments, for a period of 4 weeks. At the end of the second treatment regimen all participants will again fill out a GCSI questionnaire and SF-12 form, and undergo a C13-acetate breath test. At the end of the second treatment regimen participants will again fill out a Validation of Blinding Questionnaire.
Conditions
- Diabetic Gastroparesis
Interventions
- OTHER
-
Acupuncture
acupuncture treatment (or placebo), 20 minute treatment each; twice weekly for four weeks (total of eight treatments). repeat treatment schedule following crossover (placebo-treatment)
- PROCEDURE
-
placebo/sham acupuncture
acupuncture at sham points without skin penetration
Sponsors & Collaborators
-
Shaare Zedek Medical Center
lead OTHER
Principal Investigators
-
Noah Samuels, M.D. · Shaare Zedek Medical Center, Jerusalem, Israel
-
Joseph Lysy, M.D. · Hadassah University Hospital
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- TRIPLE
- Model
- CROSSOVER
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2009-06-30
- Primary Completion
- 2010-06-30
- Completion
- 2010-09-30
Countries
- Israel
Study Locations
More Related Trials
-
Affects of Once-daily Oral Administration of TZP-102 on the Treatment of Symptoms Associated With Diabetic Gastroparesis
NCT01452815 ·Status: COMPLETED ·Phase: PHASE2
-
Impact of Per Oral Pyloromyotomy (POP) on Glycemic Control in Diabetes
NCT04696159 ·Status: RECRUITING ·Phase: NA
-
The Effect of Single Doses of the Motilin Receptor Agonist GSK962040 in Type I Diabetic Patients With Gastroparesis
NCT00861809 ·Status: COMPLETED ·Phase: PHASE2
-
GLP-1 Receptor Agonist Use and Incidence of Retained Gastric Food on Endoscopy
NCT05875636 ·Status: COMPLETED
-
The Impact of Glucotoxicity on Gastric Emptying in Chinese Patients With Newly Diagnosed Type 2 Diabetes
NCT05284344 ·Status: COMPLETED
-
Atropin and Glucose Stimulated Insulinsecretion and the Cephalic Insulin Response
NCT01534442 ·Status: UNKNOWN ·Phase: NA
-
The Effect of Gastric Emptying on Blood Glucose Profile of Type 1 Diabetes Mellitus and Its Therapeutic Strategies
NCT06173934 ·Status: RECRUITING ·Phase: NA
-
Trial Investigating Efficacy of G-POEM
NCT05830994 ·Status: UNKNOWN ·Phase: NA
-
A Scintigraphy Study in Adults With Diabetic Gastroparesis
NCT04208698 ·Status: TERMINATED ·Phase: PHASE2
-
G-POEM for Glycemic Control in Diabetic Gastroparesis
NCT06965543 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
Trial of IW-9179 in Patients With Diabetic Gastroparesis (DGP)
NCT02289846 ·Status: COMPLETED ·Phase: PHASE2
-
Postprandial Blood Glucose Control and Gastric Emptying in Type 1 Diabetes: Pathogenetic Factors and Therapeutic Options
NCT02365740 ·Status: UNKNOWN ·Phase: NA
-
To Determine Tolerability to Glucagon Infusion in Obese Subjects
NCT02817659 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
Scintigraphy Study to Assess Gastric Emptying in Healthy Subjects Given GSK716155 or Placebo.
NCT00537719 ·Status: COMPLETED ·Phase: PHASE1
-
Effect of Tegaserod on Gastric Emptying in Patients With Diabetic Gastroparesis
NCT00390975 ·Status: TERMINATED ·Phase: PHASE4
-
Intact Vagal Innervation and Glucagon-like Peptide-1 (GLP-1) Effects
NCT01176890 ·Status: UNKNOWN ·Phase: NA
-
The Effect of GLP-1 on Glucose Uptake in the Brain and Heart in Healthy Men During Hypoglycemia
NCT00418288 ·Status: COMPLETED ·Phase: NA
-
A Study of CNSA-001 in Women With Diabetic Gastroparesis
NCT03712124 ·Status: COMPLETED ·Phase: PHASE2
-
Effect of Hyperglycemia on Gastric Emptying Interactions With Pramlintide
NCT00489645 ·Status: COMPLETED ·Phase: NA
-
Efficacy of Domperidone (a Prokinetic Agent) on Time in Range in Digestively Asymptomatic Type I Diabetic Patients With Delayed Gastric Emptying (Gastro-TIR)
NCT06695962 ·Status: NOT_YET_RECRUITING ·Phase: PHASE3
-
Amylin and Glucagon-Like Peptide-1 (GLP-1): Influence on Gastric Emptying, Appetite and Food Intake in Humans
NCT00876213 ·Status: COMPLETED
-
Effect of the Enteric Hormone Glucagon-Like Peptide (GLP-2) on the Intestinal Blood Flow in Patients With Short Bowel Syndrome
NCT00673751 ·Status: UNKNOWN ·Phase: NA
-
The Effect of GLP-1 on Glucose Uptake in the Brain and Heart in Healthy Men
NCT00256256 ·Status: COMPLETED ·Phase: NA
-
Effect of Glucagon-like Peptide 2 on Gallbladder Motility After a Meal in Young, Healthy Male Subjects
NCT03682172 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
A Pilot Study of Hemin Therapy for Gastroparesis (Diabetes Mellitus)
NCT01206582 ·Status: COMPLETED ·Phase: PHASE2